semaglutide weight loss trial sign up 7.2 mg Displays 20.7% in Phase 3b STEP Once-weekly semaglutide 2.4 mg led

Because cardiovascular events are a major driver of health care costs in patients with diabetes, previously mentioned reductions in the incidence of major cardiovascular events associated with several GLP-1 receptor agonists have the potential to translate into health economic benefits (39)

The risk is severe caloric restriction that drops below 800 to 1,000 calories per day, which triggers metabolic adaptation, muscle loss, nutrient deficiencies, and hormonal disruption

Controlling blood sugar and blood pressure using angiotensin-converting enzyme inhibitors or angiotensin receptor blockers is the current goal in DKD management [9], and no special drugs or other therapeutic options are widely used to delay DKD progression

10.1056/NEJMc1615712 55 McDonaghT

The chart above represents a starting framework, not an immovable protocol